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This issue reports a case where the authors can be congratulated
on having saved the life of a patient who originally suffered from
giant cell myocarditis and had been treated with cyclosporine
(CyA), azathioprine (AZA) and corticosteroids (PDN) for 4 years
before clinically deteriorating and been subjected to heart trans-
plantation (HTx) [1]. The pretransplant work-up included human
leukocyte antigen (HLA)-typing of both patient and donor,
screening for anti-HLA antibodies and cross-match with regard
to T- and B-cells being negative. Postoperatively, conventional
immunosuppression (CyA, AZA and PDN) was introduced. There
were three HLA Class I and one HLA Class II allele mismatches
between donor and recipient.
The ﬁrst endomyocardial biopsy (EMB) showed mild rejection
(ISHLT 1R) without C4d deposition in immunohistochemistry. The
second EMB (3 weeks postoperatively) revealed severe macrophage
(CD68+), and eosinophilic and lymphocytic inﬁltration, again
without C4d deposition. The patient developed fever without clin-
ical signs of infection and was treated under the presumption of
acute cellular rejection (ACR). After initial stabilization, the patient
developed cardiogenic shock 2 days later, which required urgent
treatment with extracorporeal membrane oxygenation, followed by
the implantation of a biventricular assist device the next day. At
that time, EMB showed severe ACR (ISHLT 3R) and antibody-
mediated rejection (AMR), strongly positive for C4d [2, 3]. The cyto-
toxic T- and B-cell cross-match tests remained negative.
The endothelial precursor cells cross-match test (EPC-XM;
XM-ONE®, AbSorber AB, Sweden) was synchronously performed
with EMBs, measuring serum levels of the amount of
antiendothelial-cell antibodies (AECAs), either against donor-
speciﬁc EPC’s or against autoreactive EPC’s (the patient’s own
EPCs). After initially being negative, donor-speciﬁc AECA became
positive at the ﬁrst EMB (ISHLT 1R), but autoreactive AECAs
were still negative. At the time of acute graft failure, the test was
surprisingly positive for both donor-speciﬁc and autoreactive
IgM antiendothelial AECA, but not for donor IgG AECA. The
authors conclude that severe AMR was caused by non-HLA,
AECAs. Epicrisis was successfully treated by plasmapheresis, in-
travenous immunoglobulin (IVIgG), rituximab, muronomab-CD3,
bortezomib and re-HTx. One month after re-HTx, the patient had
ACR (ISHLT 2R), but remained free of AMR.
During the last 15 years, AMR became a topic of major clinical
relevance. Potential explanations are improved diagnostic tests and
the rising population of patients having undergone VAD implant-
ation before HTx. Its pathophysiology remains unknown to date.
AMR is often associated with haemodynamic compromise,
increased mortality and development of graft coronary artery
disease (CAD). Younger age, congenital heart disease, positive
donor-speciﬁc cross-match, positive panel reactive antibody
(PRA) titres, sensitization to OKT3, CMV seropositivity, previous
blood transfusions and female gender have been identiﬁed as
risk factors for AMR [4].
Ongoing discussions ﬁnally led to the consensus conference
on April 20, 2010 in Chicago [5]. They also address the question
of non-HLA antibodies, such as vimentin, endothelial cells,
MICA/MICB, with a very low incidence (2/128) by using the
current XM-One technique to separate EPCs from donor blood
[6]. It was mentioned that ‘more work is required to understand
whether these assays can be used to diagnose AMR’.
The association of AMR with cardiovascular mortality, such as
death resulting from acute rejection, myocardial infarction, con-
gestive heart failure, graft failure, arrhythmia or CAD, was recent-
ly shown in paediatric HTx [7]. Such an observation supports
protocol screening for AMR. However, the need for the treat-
ment of measurable but clinically silent AMR and the algorithm
to do so, still remains to be determined. Most of the transplant
centres continue to perform event-driven and individualized
strategies, as shown in the current case report.
Due to improved diagnostic testing and recently developed
therapeutic strategies, we do have the chance to avoid or to
treat AMR individualized and sufﬁciently, either in the case of
preformed (such as in ABO incompatibility) or acquired HLA
antibodies (such as via pregnancy, prior transfusion or trans-
plant). Some may argue that most of the measures against AMR
need intravenous administration, which is difﬁcult to maintain
over the years. However, we can assume that ‘accommodation’
will occur [8]. To provide an example of how to manage such
cases successfully, we would like to share the case of accidental
B to O incompatible HTx having been rescued successfully
by anti-B antibody absorption, plasma exchange with AB
fresh frozen plasma, IVIgG, by using an anti-B antibody
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immunoadsorption column and the C1 esterase inhibitor
(C1inh, Berinert®) [9]. The HTx patient survived 5 years and
developed a histo-blood group type change of the graft from B
to O [10].
Another example is a desensitization protocol of acquired
anti-HLA Class I antibodies: a female patient underwent coronary
artery bypass grafting. Ten years later, the patient received a
gastric bypass due to adipositas permagna and colon resection
due to diverticulitis. The patient had a previous pregnancy. Due
to intra-abdominal bleeding with haemorrhagic shock, splenec-
tomy was required. Prolonged perioperative hypotension led
to an anterior myocardial infarction and congestive heart failure.
As a consequence, left ventricular assist device (LVAD) implant-
ation was required. Preoperative serum PRA levels were 43%,
reaching postoperative serum PRA levels of 59%. In ﬂow cytome-
try 10 days post-LVAD implantation, 21 different HLA Class I
antibodies were detected. The virtual cross-match (etrl.
eurotransplant.org/cms/index.php?page=services) yielded a very
low likelihood for receiving a matching cardiac allograft. As de-
sensitization protocol, we administered mycophenolic mofetil,
rituximab and repetitive Protein-A immunoadsorption. After
single rituximab administration, the absolute B-cell count
dropped to <25/µl. Figure 1 depicts the desensitization protocol
with a consecutive decrease of the PRA levels. The patient ﬁnally
underwent HTx with two unfavourable matches (HLA-B8 and
B27); we continued during the postoperative phase with
Protein-A immunoadsorption procedures. The EMB 1 week after
HTx showed slightly swollen endothelial cells, which led to the
administration of IvIgG and C1inh. Figure 2 shows immunohisto-
chemical staining of the heart biopsies. The EMB 2 weeks after
HTx showed ACR (International Society of Heart and Lung
Transplantation 2R), which was treated with methylprednisolone
Figure 2: Immunohistochemical staining of heart biopsies: positive staining is
highlighted by a brown colour. Detection of the classical complement
pathway component C4d and terminal membrane attack complex C5b-9 as
well as tissue macrophages by CD68.
Figure 1: Desensitization protocol of the patient.
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and rATG-Fresenius. Six years after HTx, the patient continues to
be ﬁne.
The current case report by Sigurdardottir et al. and our exam-
ples show that AMR is a contemporary clinical challenge, which
can be reasonable diagnosed, addressed and solved in an appro-
priate fashion.
One week after HTx (left panel) only minimal complement de-
position was observed in small capillaries and larger vessels. This
is an unspeciﬁc feature and may be observed in the immediate
peritransplant period, e.g. following graft ischaemia/reperfusion.
CD68 marks some scattered macrophages. Endothelial cells are
ﬂat and general cellularity is low. A minimal perivascular
lymphocyte-predominant inﬁltrate suggests minor ACR.
Three weeks after transplantation (right panel), there is still
only minimal C4d deposition, and slightly more C5b-9, however,
mainly localized to larger blood vessels. Macrophage counts
remain constant. The endothelial lining of only a few capillaries
appears slightly swollen, accompanied by a perivascular and
interstitial lymphocyte-predominant inﬁltrate, suggesting ACR
(top right panel). Hallmark features of AMR, including a more
generalized swelling of the endothelial lining, thrombi in small
vessels, oedema and haemorrhage as well as intravascular accu-
mulation of macrophages, were not noted.
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